Granted Patent
Utility
US 6,800,086
· Confirmation No. 1966
REDUCED FLUENCE RATE PDT
Inventor:
H. Andrew Strong
|
⬇ PDF
|
Code | Description | Pages | ||
|---|---|---|---|---|---|
| 2004-06-17 | IFEE |
Issue Fee Payment (PTO-85B) | 2 | View | |
| 2004-06-17 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 8 | View | |
| 2004-06-17 | LET. |
Miscellaneous Incoming Letter | 1 | View | |
| 2002-02-06 | TRNA |
Transmittal of New Application | 2 | View | |
| 2002-02-06 | ADS |
Application Data Sheet | 2 | View | |
| 2002-02-06 | SPEC |
Specification | 37 | View | |
| 2002-02-06 | CLM |
Claims | 2 | View | |
| 2002-02-06 | ABST |
Abstract | 1 | View |
Inventors
H. Andrew Strong
North Vancouver, CANADA
Attorneys & Agents of Record
Classification
USPC
607/88
A61K41/0057
A61K41/0071
A61N5/062
Prosecution
- Examiner
- JOHNSON III, HENRY M
- Art Unit
- 3739
- Docket No.
- 273012012400
- Confirmation No.
- 1966
Publication
- Pub. No.
- US20020173832A1
- Pub. Date
- 2002-11-21
Patent Term Adjustment
-188days
Parent
Claims priority from a provisional application
→
App. 60/266,960
Filed 2001-02-06
· Provisional Application Expired
Child
is a Continuation in-part of
→
App. 10/641,885
· US 7,753,943
Filed 2003-08-14
· Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362
Child
is a Continuation of
→
App. 10/955,158
Filed 2004-09-29
· Abandoned -- Failure to Respond to an Office Action
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, LTD.,
SALIX PHARMACEUTICALS, INC.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS IRELAND LIMITED
RELEASE OF SECURITY INTEREST
Recorded 2025-11-20
BAUSCH HEALTH IRELAND LIMITED,
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH, CANADA INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA,
VALEANT SP. Z.O.O.
RELEASE OF SECURITY INTEREST
Recorded 2025-11-20
SOLTA MEDICAL, INC.,
PRECISION DERMATOLOGY, INC.,
BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED),
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD,
SANTARUS, INC.,
MEDICIS PHARMACEUTICAL CORPORATION,
HUMAX PHARMACEUTICAL S.A.,
SOLTA MEDICAL IRELAND LIMITED,
BAUSCH & LOMB MEXICO, S.A. DE C.V.,
BAUSCH+LOMB OPS B.V.,
BAUSCH HEALTH AMERICAS, INC.,
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH HOLDCO LIMITED,
BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC),
BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA),
BAUSCH HEALTH US, LLC,
BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.,
ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.),
ORAPHARMA, INC.,
PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.),
SOLTA MEDICAL DUTCH HOLDINGS B.V.,
V-BAC HOLDING CORP.,
VRX HOLDCO LLC,
1261229 B.C. LTD.,
1530065 B.C. LTD.
RELEASE OF SECURITY INTEREST
Recorded 2025-04-08
from
BAUSCH & LOMB IRELAND LIMITED,
BAUSCH HEALTH COMPANIES INC.,
DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH,
TECHNOLAS PERFECT VISION GMBH
SECURITY INTEREST
Recorded 2021-10-05
from
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH IRELAND LIMITED,
BAUSCH HEALTH, CANADA INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA,
VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.,
VALEANT SP. Z O. O.
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded 2019-07-03
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND LIMITED,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED
SECURITY INTEREST
Recorded 2018-02-26
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND LIMITED,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED
SECURITY INTEREST
Recorded 2018-02-26
SECURITY INTEREST
Recorded 2017-07-19
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSH & LOMB PHARMA HOLDINGS CORP.,
DENDREON PHARMACEUTICALS, INC.,
DOW PHARMACEUTICAL SCIENCES, INC.,
MEDICIS PHARMACEUTICAL CORPORATION,
OBAGI MEDICAL PRODUCTS, INC.,
OMP, INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED,
VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA),
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC
SECURITY INTEREST
Recorded 2016-07-18
ADDRESS CHANGE
Recorded 2014-05-15
PATENT ASSIGNMENT AGREEMENT
Recorded 2013-12-09
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- Patent No.
- US 6,800,086
- App. No.
- 10/072,009
- Filed
- 2002-02-06
- Granted
- 2004-10-05
- Pub. No.
- US20020173832A1
- Examiner
- JOHNSON III, HENRY M
- Art Unit
- 3739
- PTA
- -188 days
External Links